NCT02693535

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4,200 (estimated)
• Sponsor: American Society of Clinical Oncology · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [e-mail], or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Detailed description

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Conditions

• Lymphoma, Non-Hodgkin
• Multiple Myeloma
• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	Palbociclib	drug
DRUG	Sunitinib	drug
DRUG	Temsirolimus	drug
DRUG	Trastuzumab and Pertuzumab	drug
DRUG	Vemurafenib and Cobimetinib	drug
DRUG	Regorafenib	drug
DRUG	Olaparib	drug
DRUG	Nivolumab and Ipilimumab	drug
DRUG	Abemaciclib	drug
DRUG	Talazoparib	drug
DRUG	Atezolizumab and Talazoparib	drug
DRUG	Tucatinib plus Trastuzumab Subcutaneous (SC)	drug
DRUG	Futibatinib	drug
DRUG	Dabrafenib plus Trametinib	Drug
DRUG	Fam-Trastuzumab Deruxtecan-Nxki (TDxD)	Drug

Timeline

• Start date: 2016-03-14
• Primary completion: 2027-12-31
• Completion: 2028-12-31
• First posted: 2016-02-26
• Last updated: 2026-04-02

Locations

174 sites across 1 country: United States